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Background: Asthma’s cost-effectiveness is a major consideration in the evaluation of its 
treatment options. Our objective was to perform a systematic review of the cost-effectiveness 
of asthma medications.
Methods: We performed a systematic search of MEDLINE, EMBASE, CINAHL, Cochrane 
Database of Systematic Reviews, OHE-HEED, Database of Abstracts of Reviews of Effects, 
Cochrane Central Register of Controlled Trials, Health Technology Assessments Database, 
NHS Economic Evaluation Database, and Web of Science and reviewed references from key 
articles between 1990 and Jan 2008.
Results: A total of 49 RCTs met the inclusion criteria. Maintenance therapy with inhaled 
corticosteroids was found to be very cost-effective and in uncontrolled asthmatics patients 
currently being treated with ICS, the combination of an ICS/LABA represents a safe, cost-
effective treatment. The simplified strategy using budesonide and formoterol for maintenance and 
reliever therapy was also found to be as cost-effective as salmeterol/fluticasone plus salbutamol. 
Omalizumab was found to be cost-effective. An important caveat with regard to the published 
literature is the relatively high proportion of economic evaluations which are funded by the 
manufacturers of specific drug treatments.
Conclusion: Future studies should be completed independent of industry support and ensure 
that the comparator arms within studies should include dosages of drugs that are equivalent.
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Asthma is a chronic disease manifested by variable airflow obstruction and airway 
inflammation.1 There has been a significant increase in the global prevalence, 
morbidity, mortality, and economic burden associated with asthma over the last 
40 years.2
The appropriate choice of asthma medication is important in achieving asthma 
control. There are two major classes of asthma medications – controllers or preventers 
which reduce inflammation in the airway, and symptom relievers which give symp-
tomatic relief. Inhaled corticosteroids (ICS) are the mainstay of anti-inflammatory 
therapy and for more severe asthma are usually combined with a long-acting β2-agonist 
(LABA). Oral corticosteroids are generally reserved for the treatment of acute asthma 
exacerbations, although some patients with severe asthma are steroid dependent. 
Leukotriene modifiers are one of the newer classes of drugs which are available in 
an oral form and act as anti-inflammatory therapy. Bronchodilators relieve the symp-
toms of asthma by relaxing airway smooth muscles and are divided into short-acting 
β2-agonists (SABA)and LABA.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Asthma is responsible for significant medical resource 
utilization and given that it is a chronic condition, cost-
effectiveness is a major consideration in the evaluation of 
treatment options.3 The costs of asthma medication have 
increased dramatically since 1985 and this is especially true 
with the availability of more expensive combination inhalers 
as well as newer biological drugs such as omalizumab.
To our knowledge, there has been no systematic review 
evaluating the cost-effectiveness of asthma medications. Our 
goal in conducting this systematic review is to evaluate the 
literature with respect to this question.
Method
Literature review
A systematic review was conducted to identify English 
language articles published between 1990 and Jan 2008 
that provided data on the cost of asthma medications. The 
following electronic databases were searched: MEDLINE, 
EMBASE, Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Cochrane Database of Systematic 
Reviews (CDSR), Health Economic Evaluation Database 
(OHE-HEED), Database of Abstracts of Reviews of Effects, 
Cochrane Central Register of Controlled Trials, Health Tech-
nology Assessments Database (Technology Assessments), 
NHS Economic Evaluation Database (Economic Evalua-
tions), and Web of Science and references were reviewed from 
key articles. Duplicate citations were identified and removed 
using RefWorks bibliographic management software.
Study selection
A total of 177 titles and abstracts of all publications identi-
fied by the primary literature search were reviewed by two 
investigators (K.B. and B.Q.), independently. The inclusion 
and exclusion criteria used for study selection are outlined 
in Table 1. The full text of the 80 potentially eligible papers, 
determined after the first level of screening, were reviewed 
to assure that each paper met the inclusion criteria for 
  population and outcomes of interest.
For cost data from the United States (US) figures were 
converted to 2008 US dollars using the medical care com-
ponent of the consumer price index from the US Bureau of 
Labor Statistics. For cost data from other countries, costs 
were first converted to 2008 currency values using the health 
or equivalent component of that country’s consumer price 
index. Figures were then converted to 2008 US dollars, 
using currency exchange rates of AUD$1.00 = USD$0.888, 
CAD$1.00 = USD$0.998, EUR∈1.00 = USD$1.477, 
GBP£1.00 = USD$1.986. If the year of the cost data was 
not reported, it was assumed to be the year of article publi-
cation. In all cases, both the original cost figures provided 
in the publications as well as the equivalent costs in 2008 
US dollars are reported. Neither intangible costs nor dis-
ability adjusted life-years (DALYs) were evaluated in this 
systematic review.
Data abstraction
The following information was abstracted from all publi-
cations: authors, year of publication, primary country of 
origin, study design and duration, whether the study was 
placebo controlled, patient characteristics (population, age, 
and gender), number of patients enrolled in each treatment 
arm, types of analysis, cost measurements, and comparative 
medications.
Methodological quality assessment
The methodological quality assessment in this review 
was divided into two parts. First, the quality of the eco-
nomic evaluations was assessed using the checklist for 
assessing economic evaluations published by Drummond 
and Jefferson4 (see Table 2). Secondly, the quality of the 
clinical effectiveness studies was assessed using modi-
fied criteria based on CRD Report No. 4.5 Study qualities 
were assessed and data were extracted by one reviewer 
and confirmed by a second reviewer. Items were scored 
as positive, negative, or unclear. Randomized controlled 
trials (RCTs) that fulfilled 50% or more of the internal 
validity items were considered of high methodological 
quality. Any disagreements between the reviewers were 
resolved through consensus.
Statistical analysis
Due to the heterogeneity between studies in terms of the 
variety of medications and unit cost data the results of the 
Table 1 Inclusion and exclusion criteria
Inclusion Exclusion
• English language •   Conference abstracts, case 
reports, letters, comments, 
editorials, and review papers
•   Studies that consider the  
costs of asthma medications
• Studies from 1990 onwards
•   Studies that consider asthma 
with other comorbidities 
(such as allergies, COPD)
•   Studies that didn’t quote 
costs in the results section
• Non-RCT trials
• Animal or in vitro studies
Abbreviations: COPD, chronic obstructive pulmonary disease; RCT, randomized 
controlled trials.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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economic evaluations did not allow a quantitative meta-
analysis to be completed.
Results
Literature search
The primary literature search identified 2,976 citations. 
After removing duplicate citations there were 2,073 unique 
citations. Manual screening of all titles and abstracts 
identified 307 articles that contained primary clinical data 
evaluating the cost of asthma treatment. Of the 307 full 
text articles retrieved and reviewed by the investigators, 
49 RCT met the inclusion criteria (see Figure 1).
Quality assessment
Most of the authors of our sample studies clearly 
described their inclusion and exclusion criteria and the 
population as well as specifying the primary outcome 
measures. Eighty-nine percent of studies were rated as 
being of high-quality. The quality of 65% of these studies 
was more than 7/10.
Characteristics of the selected studies
Of the 49 identified studies, 12 were based in the US, 16 in 
mainland Europe (mainly Sweden), 10 in the United King-
dom (UK), and two in Canada. Ten of the reviewed studies 
were multinational. Forty-seven studies involved the evalu-
ation of both the cost and efficacy of the study medication. 
In each study, comparative effects of different medications 
on asthma-related health care utilization and costs were 
reported. Study funding sources according to the articles 
are reported in Table 3.
The cost-effectiveness of the different asthma medications 
evaluated are summarized below:
Inhaled corticosteroids
The impacts of ICSs on asthma patients as well as their 
cost-effectiveness were evaluated in 18 studies.6–23 In three 
of the studies it was reported that there was a cost-benefit to 
the introduction of ICS therapy and that this therapy brought 
about significant decreases in health care utilization and 
asthma-related cost.8,11,21
Budesonide (with or without other 
asthma medications)
In fourteen studies the results of a cost-effectiveness analysis 
of the ICS budesonide versus placebo or in comparison with 
other asthma medications were reported.6,9–16,18–22 Of these, in 
five studies it was found that treatment using budesonide, over 
the long term, was more cost-effective than placebo or other 
usual asthma therapy, with a substantial reduction in hospital-
izations, emergency department visits, and school or caregiver 
work days missed (see Table 4).9,11,18,21,22 It was also shown that 
the additional drug costs were substantially offset by reduced 
use of health care services and indirect costs. In a 3-year study 
evaluating the early use of ICS conducted in eight different 
countries (Australia, Canada, China, France, Spain, Sweden, 
UK, and US), treatment with budesonide was also found to 
be cost-saving in Australia, Canada, and Sweden from both 
a health care payer and societal perspectives.9 Another study 
randomized patients to receive budesonide with three differ-
ent doses or placebo.18 The investigators found the number of 
emergency department visits, days lost from work, and days 
of hospitalization all to be lower in the budesonide groups, 
leading to significantly reduced total healthcare costs and 
increased productivity compared to placebo (P , 0.05). The 
average cost in the placebo group was found to be $37 per day 
compared with $11, $9, and $18 in budesonide 200 µg, 400 µg, 
and 800 µg daily dosing groups, respectively. In another high 
quality study, the cost-effectiveness ratio of budesonide rela-
tive to placebo was found to be decreased to $3.70 (95% CI, 
$0.10–$8.00).21
Comparing the cost-effectiveness  
ratio of different ICSs
Fluticasone propionate (FP) versus BUD
In five studies the cost differences between FP and BUD 
was explored. Although FP was found to be more expen-
sive than BUD in all studies, when the impact on outcomes 
was assessed, FP proved to be the most cost-effective 
Table  2  Criteria  for  evaluating  an  economic  analysis  based 
Drummond and Jefferson assessment method*4
  1. Was a well-defined question asked in an answerable form?
  2.   Was a comprehensive description of the competing alternatives 
provided?
  3. Was there evidence that the program’s effectiveness was established?
  4.   Were all the important and relevant costs and consequences 
identified?
  5.   Were costs and consequences measured accurately with appropriate 
physical units?
  6. Were costs and consequences credibly valued?
  7. Were costs and consequences adjusted for differential timing?
  8.   Was an incremental analysis of costs and consequences of alternatives 
performed?
  9. Was a sensitivity analysis performed?
10.   Did the presentation and discussion of the study results include all 
issues of concern to users?
*Note: All items have three possible responses, Yes (+), Cannot tell (N/A), and 
No (-).Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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option (Table 5).24–28 Delivery of the medications by dif-
ferent devices was found to have no effect on the results 
in three of the studies.24,26,28  In another study, the efficacy 
and tolerability of FP via a metered-dose inhaler and 
Volumatic spacer device was compared with nebulized 
budesonide (nBUD).25 Although the study didn’t involve 
an evaluation the cost-effectiveness of the medications, 
the cost per patient analysis for nebulized budesonide was 
found to be 1.7 to 3.5 times more expensive than FP. Given 
the expense of nebulized therapy this result would not be 
unexpected. In contrast to the above studies, in a clinical 
trial conducted in UK, it was reported that budesonide, 
whether administered once or twice daily, was a more cost-
effective treatment option than fluticasone dry-powder 
disk inhaler.27
FP versus flunisolide (FL)
In a cost-effectiveness analysis conducted in Germany, in a 
comparison of two ICS (FP and FL), the average daily treat-
ment in the FP groups was found to be higher than in the 
FL groups, however, all cost-effectiveness ratios favoured 
FP. An incremental cost-effectiveness ratio (ICER) analysis 
revealed that when switching from FL to FP, there were 
additional costs of $5.86 and $6.03 per additional symptom-
free day (SFD), and of $2.82 and $2.61 for each additional 
successfully treated patient per day, would be incurred. In 
these patients, management with FP was found to be more 
cost-effective than with FL.29
FP versus triamcinolone acetonide (TA)
In a further study, FP 250 µg twice daily was compared 
with TA 200 µg in patients with persistent asthma. It was 
found that the daily cost per successfully treated patient 
based upon a $12% increase in forced expiratory volume 
in one second (FEV1) was $6.15 for the FP treated group 
and $9.60 for the TA-treated group. In addition, the cost 
for improvement in symptoms was determined to be $18.11 
per additional SFD for FP and $23.40 per additional SFD 
for TA. The ICER that would be incurred if patients were 
switched from the less effective treatment, TA, to FP was 
$0.88 per day for an additional patient to achieve a 12% 
improvement in FEV1.30
Figure 1 Results of a systematic literature search.
Abbreviations: RCT, randomized controlled trials. 
Total citations identified (n = 2976)
Potentially relevant studies (n = 304)
Studies that met the inclusion
criteria (n = 177)
All studies (n = 80)
Final included RCT studies (n = 49)
– Asthma with other comorbidities
–N on-English text 
–C onference abstracts, case reports, letters,
anonymous authors, comments, meta-
analyses, editorials, and review papers
–N o cost analysis studies
–N o economy burden of asthma studies
–N o asthma management or asthma
intervention studies
–N o case-control studies 
–N o cohort studies
–N o surveys/data analysis
–M edications that are not available anymore
and therefore comparison is irrelevant.Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Long-acting β2 agonists
In a further study, patients with mild to moderate asthma 
were randomized to eformoterol 12 µg bid and salmeterol 
50 µg bid via either a pressurised metered dose inhaler 
(pMDI) or metered dose powder inhaler (DPI) to determine 
the cost-effectiveness of each long-acting bronchodilator in 
the treatment of asthma. Patients had been receiving at least 
200 µg/day inhaled corticosteroid at a constant dose for at 
least 4 weeks prior to study entry. Findings in the study 
indicated that the total medical costs of treating patients with 
eformoterol were significantly lower than the costs of treating 
a similar population with salmeterol via either DPI or pMDI 
($141 versus $146 or $150, respectively). The mean cost of 
achieving a SFD on salmeterol was estimated to be between 
25% (pMDI) and 41% (DPI) more than achieving the same 
result using eformoterol Turbuhaler.31
LABA versus SABA
In five studies the use of LABA or SABA medications in 
the treatment of asthma were compared.32–36 Overall, the 
mean cost-effectiveness ratios of formoterol were found 
to be higher than those for SABA. The results of three 
studies indicated that LABA (particularly formoterol) 
achieved significant improvements in effectiveness, less 
use of reliever and maintenance medication, and reduced 
resource utilization, with no increase or only a limited 
increase in health care cost compared with SABA.32,33,35 The 
first study was based on the Real-Life Effectiveness of Oxis 
Turbuhaler as needed in asthmatic patients (RELIEF), and 
evaluated the cost-effectiveness of formoterol 4.5 µg and 
salbutamol 200 µg in Sweden and Spain. At study entry, 
76% of patients were being treated with ICS and 31% with 
long-acting bronchodilators. Compared to salbutamol, the 
authors found formoterol to be associated with statistically 
significant improvements in effectiveness, reduced health 
care resource utilization, and with lower health care costs 
in the patients with severe disease.32 In a further study, 
  formoterol was compared to terbutaline in combination 
with inhaled steroids in patients with moderate to severe 
asthma. In this study lower costs of treatment with for-
Table 4 Studies in which budesonide was found to be more cost-effective than placebo or other usual asthma therapy
Ref. # Study duration Country Budesonide versus placebo Budesonide Placebo
Health care cost reduction 
(patient/yr)
P 
value
Total costs 
(patient/yr)
Total costs 
(patient/yr)
9 3 yrs Australia $21 ,0.05 NA NA
Sweden
Canada
$48  
$44
0.01  
,0.1
11 6 m US NA NA $3,828 $5,180
18 6 m US NA NA BT 200 µg, n = 53, $11 
BT 400 µg, n = 55, $9 
BT 800 µg, n = 57, $18
$37
21 3 yrs US $11.30, Health care perspective 
$3.70, Societal perspective
NA NA NA
22 3 yrs US 192/3 yr NA NA NA
Notes: All currencies have been converted and inflated to year 2008. Yr = year(s).
Table 3 Study funding sources according to the articles
Reference Year of  
publication
Country/ies Sponsoring  
companies
13 2006 Multicountry AstraZeneca 
16 2006 Sweden AstraZeneca Sweden
21 2003 US AstraZeneca Sweden
25 1998 UK Glaxo Wellcome,  
UK Ltd.
26 1998 Germany Glaxo Wellcome
27 1996 UK Astra Pharmaceuticals 
Ltd.
29 1999 Germany Glaxo Wellcome
30 2000 US Glaxo Wellcome, Inc.
31 2000 UK AstraZeneca 
Pharmaceuticals UK Ltd.
32 2005 Multicountry AstraZeneca R&D; 
Lund
36 1998 Multicountry Novartis
37 1993 Netherlands Netherland’s Health 
Research Promotion 
Program (SGO), Glaxo, 
Astra Pharmaceuticals 
and Boehringer 
Ingelheim
41 2002 UK GlaxoSmithKline Inc.
42 2004 US GlaxoSmithKline Inc.
43 2005 Multicountry GlaxoSmithKline Inc.
45 2001 US GlaxoSmithKline Inc.
47 2002 US GlaxoSmithKline Inc.
48 2007 Sweden Novartis Pharma AG
49 2006 Multicountry Novartis
50 1996 UK Glaxo Wellcome 
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Dovepress 
Dovepress
38
Bahadori et al
moterol ($495 versus $542 per patient, respectively) were 
demonstrated.33 Everden et al found that in children with 
symptomatic asthma who were receiving SABA and ICS, 
treatment with eformoterol was significantly more effec-
tive and less expensive than treatment with salmeterol 
(P = 0.034 and P , 0.001).35 In contrast to the above 
studies, in a high quality multinational trial, the cost-
effectiveness of formoterol 12 mg metered dose powder 
inhaler was compared with salmeterol 50 mg inhaled twice 
daily via Diskhaler in adults with asthma and in which 
patients were required to keep the dose of ICSs constant 
throughout the study. In this study no evidence was found 
to suggest that either treatment was more cost-effective 
than the other.36
ICSs plus LABA
In eight studies the cost-effectiveness of adding formoterol or 
salbutamol to BUD in the treatment of moderate, persistent 
asthma was demonstrated.6,8,12–14,16,20,37 In a cost-effectiveness 
analysis, a combination of inhaled LABA plus ICS therapy 
was compared with LABA + placebo (PL) in children with 
asthma aged 7–16 years. It was found that annual drug 
acquisition costs for the LABA + ICS were $478 higher 
than for the LABA + PL group. Annual savings due to 
reduced health care utilization, excluding the cost of study 
drugs by the group receiving LABA + ICS compared with 
LABA + PL, were estimated to be about $272 per patient. 
The ICER of LABA + ICS was estimated to be about $174 
per 10% increase in FEV1, suggesting the combination of 
LABA + ICS to be a cost-effective treatment option.37
Adding formoterol to budesonide was evaluated in 
several studies and it was found to be cost-effective in 
one study,6 and less costly in a single inhaler than separate 
inhalers in two other studies.12,20 In another study adjust-
able maintenance dosing with budesonide/formoterol (one 
inhalation twice daily, stepping up to four inhalation twice 
daily for 1 week if asthma worsened) versus fixed dosing 
(two inhalation twice daily) was compared for 12 weeks in 
adults with asthma and significantly lower asthma-related 
direct costs were found in the adjustable maintenance dosing 
with budesonide/formoterol in a single inhaler (mean: $339 
versus $448; P , 0.001).8 In another study patients were 
randomized to twice-daily treatment with BUD 100 µg, 
BUD 100 µg plus formoterol 4.5 µg, BUD 200 µg, or 
BUD 200 µg plus formoterol 4.5 µg for 12 months and the 
cost-effectiveness of both treatments was compared.14 The 
researchers found that BUD 200 µg plus formoterol 4.5 µg 
was more cost-effective than BUD 100 µg plus formoterol 
4.5 µg. The ICER for this comparison was found to be 
$2.99 per SFD gained. Results from an economic analysis 
comparing the strategy of budesonide/formoterol (Symbi-
cort®) Maintenance and Reliever Therapy (SMART) versus 
salmeterol/fluticasone (SFC) plus salbutamol demonstrated 
that the SMART strategy was a cost-effective treatment 
option from a societal cost perspective, compared with 
SFC, in Italy, Germany, France, and the UK. The total cost 
of the SMART strategy was found to be a significantly less 
costly treatment option than SFC ($1,416 versus $1,590; 
P = 0.024).13 In another study it was investigated whether 
the SMART concept could be applied also with only one 
dose/day as background maintenance therapy. The once 
daily SMART group (1 × SMART) was compared with 
a SMART group using twice the maintenance dose (2 × 
SMART). To make the comparison as strong as possible, 
a third group was treated with a fixed high maintenance 
dose budesonide/formoterol (FIX), (4-fold higher than the 
once-daily SMART group), plus formoterol as needed (2 × 
2FIX + Formoterol). Switching patients from 2 × 2FIX + F 
treatment regimen to 2 × SMART was found to reduce the 
cost of drugs by $13,721.16
Table 5 Cost comparison of fluticasone and budesonide
Ref. #  Medication and delivery Dose Cost per successfully treated patient
FP BUD FP BUD
24 FP diskhaler versus 
BUD reservoir dry powder device
200 400 $22.77/w $24.41/w
25 FP via MDI and Volumatic spacer  
versus BUD nebulizer
1 mg 2 and 4 mg $158.04 $273.75, 2 mg 
$554.29, 4 mg
26 FP MDI versus BUD Turbuhaler 250 600 $3.97/d $4.87/d
27 FP dry powder disk inhaler device or  
BUD Turbuhaler 
200 200 
400
$4.12/d $2.85/d, BUD 200 
$2.37/d, BUD 400
28 FP Accuhaler versus. BUD Turbuhaler 200 400 $56.84/w $93.01/w
Note: All currencies have been converted and inflated to year 2008.
Abbreviations: W, week; d, day; N/A, not available; FP, fluticasone propionate; BUD, budesonide; MDI, metered-dose inhaler. Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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SFC vs ICSs
In five studies the cost-effectiveness of SFC 50/100 µg with 
fluticasone propionate 100 µg was compared.15,38–41 Despite 
the higher drug costs for SFC, the cost per successfully 
treated week was found to be lower for SFC than FP alone 
in all studies. The ICERs reported in three studies were esti-
mated to be $20.91, $30.12, and $26.04, respectively.38,40,41 
Similarly, the result of a prospective economic analysis 
comparing SFC 50/250 mg twice daily versus BUD 800 mg 
twice daily in adults and adolescents with asthma suggested 
that SFC was more cost-effective than BUD alone. The cost-
effectiveness ratio was found to be $32.69 and $48.08 in the 
SFC group and the BUD group, respectively.15
SFC versus ICS with leukotriene modifiers (LTM)
In three studies SFC versus ICS plus montelukast were 
compared, and it was found that SFC had superior clinical 
benefits and cost-effectiveness compared to the montelukast-
containing regimen.42–44 The result of the ICER analyses 
revealed SFC to be dominant over ICS plus montelukast.42,43 
Similarly, the results of a combined analysis of four clini-
cal trials, two comparing SFC with montelukast and two 
comparing FP with montelukast as initial asthma therapy, 
demonstrated that first line treatment with SFC was asso-
ciated with a significant lower risk of an asthma-related 
exacerbation and lower exacerbation-related costs. Mean 
daily exacerbation costs for patients who experienced an 
asthma-related exacerbation were $35 for SFC, $153 for FP, 
and $184 for montelukast.44
Leukotriene receptor antagonist (LTRA) versus ICS
In one study the differences between LTRA (zafirlukast) ver-
sus fluticasone propionate 88 µg twice daily and health care 
resource utilization in asthma patients were examined and the 
mean daily cost of asthma treatment was found to be $2.66 
per patient for patients in the FP group and $4.17 for those in 
the zafirlukast group. Using symptom-free days as an effec-
tiveness parameter yielded a mean daily cost-efficacy ratio of 
$7.96 per symptom-free day for the FP group and $21.63 for 
the zafirlukast group. Results of the study supported the use 
of FP as first-line treatment in patients with persistent asthma 
previously treated with SABA alone.45
LTRA vs SFC
In two studies the relative cost-effectiveness of twice-daily 
treatment with SFC was determined compared to once-daily 
treatment with montelukast as an initial maintenance therapy 
in patients with persistent asthma uncontrolled on short-
acting β2- agonist therapy alone. In both studies it was found 
the use of SFC to be more cost-effective than montelukast. 
The ICER in both studies showed that the additional costs 
to achieve the benefits with SFC were minimal – $2.89 and 
$1.62, respectively.46,47
Omalizumab
In two studies the cost-effectiveness of omalizumab was 
evaluated.48,49 In the first study data from the ETOPA study 
were gathered and it was suggested that omalizumab was a 
more cost-effective treatment for patients with inadequately 
controlled severe persistent allergic asthma; however, their 
analysis was based on a small open-label trial, and was lim-
ited to participants who were responsive to omalizumab.48 
The INNOVATE study was a multinational study, which 
estimated the cost-effectiveness of adding omalizumab to 
optimal standard therapy in patients with severe persistent 
asthma from a societal perspective. The results showed 
that omalizumab provided cost offsets of improved quality 
of life and had an attractive ICER in patients targeted as a 
selected subgroup of severe patients with allergic asthma 
who were symptomatic despite best available care and who 
had an increased risk of needing emergency health care dur-
ing acute asthma exacerbations. Omalizumab as an add-on 
therapy was estimated to cost an additional $57,600 for 0.76 
additional quality adjusted life years (QALYs), resulting in 
an ICER of $75,568. This is a relatively high dollar amount 
per QALY.49
Cromoglycate versus ICSs
In two studies the cost-effectiveness of ICSs versus sodium 
cromoglycate in asthma patients was examined.7,50 In the 
first study, the cost-effectiveness of sodium cromoglycate 
was compared with BUD in children age 5–11 years. It 
was found that budesonide, when taken for maintenance 
treatment, after an initial period of stabilizing treatment 
with BUD, resulted in lower average annual cost ($1,921 
versus $2,530) and fewer drug switches than did a strat-
egy with sodium cromoglycate.7 In the second study, the 
cost-effectiveness of FP versus sodium cromoglycate was 
examined in a group of children with asthma and found 
that irrespective of the symptomatic or clinical measures of 
success that were used, there were better outcomes using FP 
than sodium cromoglycate. The average cost per treatment 
success for FP was approximately $50 compared with $125 
for sodium cromoglycate.50Journal of Asthma and Allergy 2010:3 submit your manuscript | www.dovepress.com
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Discussion
Evaluating the cost-effectiveness of asthma medications is 
important to ensure the most appropriate choice of asthma 
medication. It is also particularly relevant due to the   increasing 
burden of illness and the rising costs associated with manag-
ing asthma. Assessing differences in health care costs for the 
treatment of asthma is challenging because of the difficulty in 
deriving a single representative cost for each drug.
The present systematic review (SR) was aimed at review-
ing the literature on the pharmaco-economics of asthma 
treatment. It adds to the current literature base by providing 
a systematic review of studies looking at the costs and/or 
effectiveness of asthma medications. Of the 80 reviewed 
articles, 49 studies met the inclusion criteria.
Early intervention and long term treatment with anti-
inflammatory therapy using an ICS was found to be a cost-
effective treatment option that demonstrated a significant 
decrease in health care utilization and asthma-specific costs. 
However, higher doses of ICS were not found to be more 
cost-effective. Among the ICSs, FP both 100 µg/day and 
200 µg/day proved to be the most cost-effective treatment. 
For early asthma treatment comparing ICS to a LTRA, ICS 
was associated with lower asthma-related costs. Similarly, the 
cromones were found to be a cost-effective medication when 
compared to placebo but not when compared to ICSs.
Although in several studies in this SR, BDP was reported as 
being a dominant cost-saving intervention, no published eco-
nomic evaluations provided any evidence of the superiority of 
BDP compared to FP. Another systematic review supports the 
findings in this review regarding BDP as the current cheapest 
ICS product at doses of 200, 400, and 800 µg/day.51
In our SR adding inhaled LABA to low to moderate 
doses of ICS was found to be cost-effective, and adjustable 
maintenance dosing budesonide and formoterol in a single 
inhaler was found to maintain significantly lower cost than 
a fixed dosing strategy.6,8,12–14,17,20 These results indicate 
that when a patient is not adequately controlled on inhaled 
corticosteroid alone and an additional treatment step is 
required, switching to a combination of inhaled steroid and 
LABA combination in a single inhaler can improve asthma 
control without increasing costs, and may even provide 
cost savings. Although costs per successfully treated week, 
episode free day (EFD), and SFD for salmeterol/fluticasone 
were found to be considerably lower than for other ICSs, 
LTMs, and ICS plus LTMs;14,38–44 the introduction of the 
SMART strategy was found to be incrementally a further 
cost-effective management strategy based on improved 
patient outcomes.13,16
In several studies it was demonstrated that the addition 
of omalizumab to standard therapy reduced the frequency 
of asthma exacerbations, emergency department visits, and 
hospitalizations.48,49 However, omalizumab is more expensive 
than any other asthma medication. The incremental costs 
associated with omalizumab seem considerably high com-
pared with those of other controller medications. Therefore it 
needs to be targeted to the treatment of patients with poorly 
controlled asthma despite the use of other therapies.
Conclusion
Cost-effectiveness analyses provide important data that 
should be considered when selecting treatment regimens for 
asthma. The result of this systematic review has demonstrated 
that maintenance therapy with ICS is very cost-effective. In 
addition, in patients with asthma uncontrolled on ICS the 
combination of an ICS/LABA in a single inhaler represents a 
safe, cost-effective, and convenient treatment. The simplified 
strategy using budesonide and formoterol for maintenance 
and reliever therapy was also found to be feasible, safe, 
and at least as cost-effective as salmeterol/fluticasone plus 
salbutamol. Omalizumab, although expensive, was found in 
carefully selected patients to be cost-effective. An important 
caveat with regard to the published literature in this area is 
the relatively high proportion of economic evaluations which 
are funded by the manufacturers of specific drug treatments. 
Future studies should be completed independent of industry 
support and also should ensure that the comparator arms 
within studies include dosages of drugs that are equivalent.
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